Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02542293
Title Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca

lung non-small cell carcinoma


Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Durvalumab + Tremelimumab

Carboplatin + Paclitaxel

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST